News Column

Paragon BioTeck, Inc. Receives FDA Clearance for Comfortear Lacrisolve Absorbable Punctum Plug

July 9, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Paragon BioTeck, Inc., a privately held biopharmaceutical and medical device company specializing in the development of ophthalmic pharmaceuticals, devices and therapies, announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Comfortear® Lacrisolve™ Absorbable Punctum Plug (see also Paragon BioTeck, Inc.).

"Receiving FDA 510(k) clearance for this device is an important milestone for Paragon. Dry eye affects over 4.8 million people in the U.S. and, keeping with Paragon's ultimate goal to protect and preserve eyesight, the Comfortear Lacrisolve Absorbable Punctum Plug is a great addition to our portfolio of FDA regulated ophthalmic products," says Lauren M-C Bluett, Director of Quality Assurance.

Keywords for this news article include: Paragon BioTeck Inc, Government Agencies Offices and Entities.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters